Demand for germline hereditary cancer genetic testing has increased because of reduced cost, gene discovery, expanding indications, and precision cancer therapies. The traditional model for germline ...
Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022 Demand for germline hereditary cancer genetic testing has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results